ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
Oncotelic Therapeutics (OTCQB:OTLC) announced its upcoming presentations at SITC 2024, led by Dr. Cynthia Lee, VP of R&D. The company will present three abstracts focusing on TGFB2 therapeutics and cancer research:
1. Abstract 198: Examining TGFB2 mRNA levels' interaction with various markers in PDAC survival
2. Abstract 218: Studying prognostic impact of TGFB2 mRNA levels in low-grade gliomas
3. Abstract 1444: Meta-analysis comparing treatments for unresectable PDAC tumors
Dr. Lee, who leads the company's R&D programs and GMP facility in San Diego, will present the Sapu Bio pipeline of TGFB2 therapeutics.
Oncotelic Therapeutics (OTCQB:OTLC) ha annunciato le sue prossime presentazioni al SITC 2024, guidate dalla Dr.ssa Cynthia Lee, VP di R&S. L'azienda presenterà tre abstract incentrati sulle therapeutiche TGFB2 e la ricerca sul cancro:
1. Abstract 198: Esaminare l'interazione dei livelli di mRNA di TGFB2 con vari marker nella sopravvivenza del PDAC
2. Abstract 218: Studio dell'impatto prognostico dei livelli di mRNA di TGFB2 nei gliomi a basso grado
3. Abstract 1444: Meta-analisi a confronto dei trattamenti per tumori PDAC non resezionabili
La Dr.ssa Lee, che guida i programmi di R&S dell'azienda e l'impianto GMP a San Diego, presenterà il pipeline Sapu Bio di terapeutiche TGFB2.
Oncotelic Therapeutics (OTCQB:OTLC) anunció sus próximas presentaciones en el SITC 2024, lideradas por la Dra. Cynthia Lee, VP de I+D. La compañía presentará tres resúmenes centrados en terapéuticas TGFB2 y la investigación sobre el cáncer:
1. Resumen 198: Examinando la interacción de los niveles de ARNm de TGFB2 con varios marcadores en la supervivencia del PDAC
2. Resumen 218: Estudio del impacto pronóstico de los niveles de ARNm de TGFB2 en gliomas de bajo grado
3. Resumen 1444: Meta-análisis comparativo de tratamientos para tumores de PDAC irresecables
La Dra. Lee, quien lidera los programas de I+D de la compañía y la instalación GMP en San Diego, presentará el pipeline de Sapu Bio de terapéuticas TGFB2.
온코텔릭 제약(OTCQB:OTLC)이 SITC 2024에서 곧 있을 발표를 발표했으며, 이 발표는 연구개발 VP인 신시아 리 박사가 이끌게 됩니다. 이 회사는 TGFB2 치료제 및 암 연구에 중점을 둔 세 가지 초록을 발표할 예정입니다:
1. 초록 198: PDAC 생존에서 TGFB2 mRNA 수준과 다양한 마커 간의 상호 작용 조사
2. 초록 218: 저등급 교모세포종에서 TGFB2 mRNA 수준의 예후적 영향 연구
3. 초록 1444: 절제가 불가능한 PDAC 종양 치료 비교 메타 분석
신시아 리 박사는 샌디에이고에서 회사의 R&D 프로그램 및 GMP 시설을 이끌며 TGFB2 치료제의 Sapu Bio 파이프라인을 발표할 것입니다.
Oncotelic Therapeutics (OTCQB:OTLC) a annoncé ses prochaines présentations lors du SITC 2024, dirigées par le Dr Cynthia Lee, VP de R&D. La société présentera trois résumés axés sur les thérapeutiques TGFB2 et la recherche sur le cancer :
1. Résumé 198 : Examen de l'interaction des niveaux d'ARNm de TGFB2 avec divers marqueurs dans la survie du PDAC
2. Résumé 218 : Étude de l'impact pronostique des niveaux d'ARNm de TGFB2 dans les gliomes de bas grade
3. Résumé 1444 : Méta-analyse comparant les traitements des tumeurs PDAC non résécables
Le Dr Lee, qui dirige les programmes de R&D de la société et l'installation GMP à San Diego, présentera le pipeline Sapu Bio des thérapies TGFB2.
Oncotelic Therapeutics (OTCQB:OTLC) hat seine bevorstehenden Präsentationen auf dem SITC 2024 angekündigt, die von Dr. Cynthia Lee, VP für F&E, geleitet werden. Das Unternehmen wird drei Abstracts vorstellen, die sich auf TGFB2-Therapeutika und die Krebsforschung konzentrieren:
1. Abstract 198: Untersuchung der Interaktion von TGFB2-mRNA-Spiegeln mit verschiedenen Markern im Überleben von PDAC
2. Abstract 218: Untersuchung der prognostischen Auswirkungen von TGFB2-mRNA-Spiegeln bei niedriggradigem Gliom
3. Abstract 1444: Meta-Analyse zum Vergleich von Behandlungen für nicht resektable PDAC-Tumore
Dr. Lee, die die F&E-Programme des Unternehmens und die GMP-Einrichtung in San Diego leitet, wird die Sapu Bio-Pipeline der TGFB2-Therapeutika präsentieren.
- Company's research progress demonstrated through multiple scientific presentations at major conference
- Operational GMP facility in San Diego indicates manufacturing capabilities
- None.
AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://www.sitcancer.org/home.
Dr. Lee has been leading our R&D programs for the past several years including the buildout of our GMP facility in San Diego. The presentations are:
Abstract Number 198: TGFB2 mRNA levels prognostically interact with Interferon-alpha receptor activation of IRF9 and IFI27, and makers for tumor-associated macrophages impacting overall survival in PDAC. Authors Sanjive Qazi, Cynthia Lee, Vuong Trieu
Abstract Number 218: Evaluating the prognostic impact of Transforming growth factor beta 2 mRNA levels, in conjunction with Interferon-gamma receptor activation of IRF5 and expression of CD276/B7-H3 in low-grade gliomas. Authors Sanjive Qazi, Anthony Maida, Vuong Trieu
Abstract Number 1444: Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in PDAC patients harboring unresectable tumors treated with mFOLFIRINOX or FOLFIRINOX. Authors Vuong Trieu, Sanjive Qazi, Seymour Fein, Anthony Maida, Tenshang Joh
About Oncotelic
Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.
Contact Information:
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com
FAQ
What abstracts will Oncotelic Therapeutics (OTLC) present at SITC 2024?
Who will present Oncotelic's (OTLC) TGFB2 therapeutics pipeline at SITC 2024?
Where is Oncotelic's (OTLC) GMP facility located?
